Laparoscopic repeat surgery for gastro-oesophageal reflux disease: Results of the analyses of a cohort study of 117 patients from a multicenter experience.


Journal

International journal of surgery (London, England)
ISSN: 1743-9159
Titre abrégé: Int J Surg
Pays: United States
ID NLM: 101228232

Informations de publication

Date de publication:
Apr 2020
Historique:
received: 23 11 2019
revised: 20 02 2020
accepted: 03 03 2020
pubmed: 15 3 2020
medline: 10 4 2020
entrez: 15 3 2020
Statut: ppublish

Résumé

Short and long-term outcomes after repeat anti-reflux surgery (RARS) are still debated and generally not considered as satisfying as after primary anti-reflux surgery (PARS). The aim of this study was to evaluate functional outcomes after RARS and risk factors associated to intra-operative and post-operative complications. This is a multicenter retrospective survey from four European laparoscopic centers. Patients who underwent elective RARS from January 2005 to October 2017 for dysphagia or for persistent reflux disease refractory to medical treatment were analyzed. Data on demographic characteristics, including type and timing of previous operations as well as intra-operative details (surgical technique, type of RARS, conversion to open surgery, prosthetic material placement) were collected. Patients who underwent operations in the emergency setting, interventions mixed with bariatric procedures and PARS performed in other surgical departments were not included in this study. Primary endpoint of this study was to evaluate risk factors associated with intraoperative and postoperative complications. Secondary endpoint was to evaluate clinical outcomes and to identify any possible correlation with clinical and surgical parameters. Among 1662 patients who underwent PARS, failure occurred in 174 (10.5%) patients. Repeat surgery was performed in 117 (7%) patients, after a mean time of 80 months (range 4-315). RARS was carried out laparoscopically in 88% of cases. Prosthetic mesh to reinforce hiatoplasty was used in 22.2% of patients. Intra-operative upper gastro-intestinal tract's injuries occurred in 6 (5.1%) patients. Perioperative mortality was nil and 13 (11.1%) patients experienced postoperative complications. Mean length of hospital stay was 9.6 ± 6.4 days. Based on a multivariable analysis, age >70 years (OR 1.074, C.I.95% 1.018-1.133, p = 0.008) and body mass index (BMI) < 23 (OR 0.172, C.I.95% 0.052-0.568, p = 0.004) were independently associated to postoperative complications. After a mean follow-up time of 36 months (range 6-107), 24 (20.5%) patients presented recurrent symptoms. Based on a multivariable analysis, early onset of dysphagia (OR 3.539, C.I.95% 1.254-9.990, p = 0.017), open approach (OR 4.505, C.I.95% 1.314-15.442, p = 0.016) and the use of prosthetic material (OR 2.790, C.I.95% 0.930-8.776, p = 0.047) were significantly associated to good clinical outcomes. Repeat anti-reflux surgery is a safe and feasible procedure in high-volume centers, with acceptable perioperative outcomes. Long-term results are favorable with a success rate of almost 80%. Advanced age (>70 years) and low BMI (<23 kg/m

Sections du résumé

BACKGROUND BACKGROUND
Short and long-term outcomes after repeat anti-reflux surgery (RARS) are still debated and generally not considered as satisfying as after primary anti-reflux surgery (PARS). The aim of this study was to evaluate functional outcomes after RARS and risk factors associated to intra-operative and post-operative complications.
METHODS METHODS
This is a multicenter retrospective survey from four European laparoscopic centers. Patients who underwent elective RARS from January 2005 to October 2017 for dysphagia or for persistent reflux disease refractory to medical treatment were analyzed. Data on demographic characteristics, including type and timing of previous operations as well as intra-operative details (surgical technique, type of RARS, conversion to open surgery, prosthetic material placement) were collected. Patients who underwent operations in the emergency setting, interventions mixed with bariatric procedures and PARS performed in other surgical departments were not included in this study. Primary endpoint of this study was to evaluate risk factors associated with intraoperative and postoperative complications. Secondary endpoint was to evaluate clinical outcomes and to identify any possible correlation with clinical and surgical parameters.
RESULTS RESULTS
Among 1662 patients who underwent PARS, failure occurred in 174 (10.5%) patients. Repeat surgery was performed in 117 (7%) patients, after a mean time of 80 months (range 4-315). RARS was carried out laparoscopically in 88% of cases. Prosthetic mesh to reinforce hiatoplasty was used in 22.2% of patients. Intra-operative upper gastro-intestinal tract's injuries occurred in 6 (5.1%) patients. Perioperative mortality was nil and 13 (11.1%) patients experienced postoperative complications. Mean length of hospital stay was 9.6 ± 6.4 days. Based on a multivariable analysis, age >70 years (OR 1.074, C.I.95% 1.018-1.133, p = 0.008) and body mass index (BMI) < 23 (OR 0.172, C.I.95% 0.052-0.568, p = 0.004) were independently associated to postoperative complications. After a mean follow-up time of 36 months (range 6-107), 24 (20.5%) patients presented recurrent symptoms. Based on a multivariable analysis, early onset of dysphagia (OR 3.539, C.I.95% 1.254-9.990, p = 0.017), open approach (OR 4.505, C.I.95% 1.314-15.442, p = 0.016) and the use of prosthetic material (OR 2.790, C.I.95% 0.930-8.776, p = 0.047) were significantly associated to good clinical outcomes.
CONCLUSIONS CONCLUSIONS
Repeat anti-reflux surgery is a safe and feasible procedure in high-volume centers, with acceptable perioperative outcomes. Long-term results are favorable with a success rate of almost 80%. Advanced age (>70 years) and low BMI (<23 kg/m

Identifiants

pubmed: 32169573
pii: S1743-9191(20)30216-8
doi: 10.1016/j.ijsu.2020.03.004
pii:
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

121-127

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2020 IJS Publishing Group Ltd. Published by Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest Authors declare no conflict of interest.

Auteurs

Fabrizio Panaro (F)

Department of Surgery, Division of GI Surgery and Transplantation, Hôpital Saint Eloi, CHU-Montpellier, France. Electronic address: f-panaro@chu-montpellier.fr.

Piera Leon (P)

Department of Surgery, Division of GI Surgery and Transplantation, Hôpital Saint Eloi, CHU-Montpellier, France.

Thierry Perniceni (T)

Department of Digestive, Oncologic and Metabolic Surgery, Institute Mutualiste Montsouris, Paris, France, Université Paris Descartes.

Giorgio Bianchi (G)

Department of Digestive, Oncologic and Metabolic Surgery, Institute Mutualiste Montsouris, Paris, France, Université Paris Descartes.

Francois-Regis Souche (FR)

Department of Surgery, Division of GI and Mini-invasive Surgery, Hôpital Saint Eloi, CHU- Montpellier, France.

Jean Michel Fabre (JM)

Department of Surgery, Division of GI and Mini-invasive Surgery, Hôpital Saint Eloi, CHU- Montpellier, France.

Vito De Blasi (V)

Division of General and Mini-invasive Surgery, CHL-Luxembourg, Luxembourg.

Santiago Azagra (S)

Division of General and Mini-invasive Surgery, CHL-Luxembourg, Luxembourg.

Grégory Marin (G)

Department of Statistical Medical Analysis Unit, CHU-Montpellier, France.

Giusy Giannandrea (G)

Department of Surgery, Division of GI Surgery and Transplantation, Hôpital Saint Eloi, CHU-Montpellier, France.

Brice Gayet (B)

Department of Digestive, Oncologic and Metabolic Surgery, Institute Mutualiste Montsouris, Paris, France, Université Paris Descartes.

Francis Navarro (F)

Department of Surgery, Division of GI Surgery and Transplantation, Hôpital Saint Eloi, CHU-Montpellier, France.

David Fuks (D)

Department of Digestive, Oncologic and Metabolic Surgery, Institute Mutualiste Montsouris, Paris, France, Université Paris Descartes.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH